Management of Residual or Recurrent Disease Following Thermal Ablation of Renal Cortical Tumors
Name:
133-Article Text-1672-1-10-202 ...
Size:
175.5Kb
Format:
PDF
Description:
Final Published Version
Author
Loloi, JustinShingleton, W. Bruce
Nakada, Stephen Y.
Zagoria, Ronald J.
Landman, Jaime
Lee, Benjamin R.
Matin, Surena F.
Ahrar, Kamran
Leveillee, Raymond J.
Cadeddu, Jeffrey A.
Raman, Jay D.
Affiliation
Univ Arizona, Coll MedIssue Date
2020-06-09
Metadata
Show full item recordPublisher
CODON PUBLICATIONSCitation
Loloi, J., Shingleton, B., Nakada, S., Zagoria, R., Landman, J., Lee, B., ... & Raman, J. (2020). Management of Residual or Recurrent Disease Following Thermal Ablation of Renal Cortical Tumors. Journal of Kidney Cancer and VHL, 7(2), 1-5.Journal
JOURNAL OF KIDNEY CANCER AND VHLRights
Copyright © Loloi J et al. License: This open access article is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0).Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Management of residual or recurrent disease following thermal ablation of renal cortical tumors includes surveillance, repeat ablation, or surgical extirpation. We present a multicenter experience with regard to the management of this clinical scenario. Prospectively maintained databases were reviewed to identify 1265 patients who underwent cryoablation (CA) or radiofrequency ablation (RFA) for enhancing renal masses. Disease persistence or recurrence was classified into one of the three categories: (i) residual disease in ablation zone; (ii) recurrence in the ipsilateral renal unit; and (iii) metastatic/extra-renal disease. Seventy seven patients (6.1%) had radiographic evidence of disease persistence or recurrence at a median interval of 13.7 months (range, 1-65 months) post-ablation. Distribution of disease included 47 patients with residual disease in ablation zone, 29 with ipsilateral renal unit recurrences (all in ablation zone), and one with metastatic disease. Fourteen patients (18%) elected for surveillance, and the remaining underwent salvage ablation (n = 50), partial nephrectomy (n = 5), or radical nephrectomy (n = 8). Salvage ablation was successful in 38/50 (76%) patients, with 12 failures managed by observation (3), tertiary ablation (6), and radical nephrectomy (3). At a median follow-up of 28 months, the actuarial cancer-specific survival and overall survival in this select cohort of patients was 94.8 and 89.6%, respectively.Note
Open access journalISSN
2203-5826Version
Final published versionae974a485f413a2113503eed53cd6c53
10.15586/jkcvhl.2020.133
Scopus Count
Collections
Except where otherwise noted, this item's license is described as Copyright © Loloi J et al. License: This open access article is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0).